Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP

Exclusion Criteria

• •Uncontrollable systemic infection;
• •Known allergy to bortezomib;
• •Expected survival time \<1 week;
• •Pregnant or lactating women (women of childbearing age have a positive pregnancy test at baseline or have not received a pregnancy test. Postmenopausal women must be at least 12 months after menopause);
• •If the creatinine level is ≥200μmol/l (1.5mg/dl), the levels of transaminase and bilirubin are 2 times higher than the upper limit of normal (except due to the primary disease);
• •Known congenital TTP or a clear family history of TTP;
• •Other diseases that cause microangiopathic hemolysis and thrombocytopenia, such as DIC, APS, HUS, malignant hypertension, transplantation-related microangiopathy;
• •active malignant tumors (except skin basal cell carcinoma or cervical carcinoma in situ) ( have not been treated or recurred within 5 years before signing the informed consent);
• •peripheral neuropathy;
• •Patients or family members cannot understand the conditions and goals of this study;
• •The investigator believes that the patient should not participate in any other situations in this trial.